Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas tool Copy Portfolio
Close

Salarius Pharmaceuticals Inc (SLRX)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Salarius Pharmaceuticals's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
0.4945 +0.0242    +5.15%
16:00:59 - Closed. Currency in USD ( Disclaimer )
After Hours
0.4933
-0.0012
-0.24%
17:40:31 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 40,974
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 0.4610 - 0.4948
Salarius Pharmaceuticals 0.4945 +0.0242 +5.15%

SLRX Recent Sentiments

 
This page contains information on users’ sentiments for the Salarius Pharmaceuticals Inc stock, which are displayed both on charts of different periods of time and on a detailed table.
Start Date Username Call Open Rate End Date Chg. %
May 10, 2024 SAUL NEGRELLI   0.4830 May 13, 2024 @ 0.5000 +3.52%
Apr 29, 2024 Giordano Muffatti   0.5100 Apr 29, 2024 @ 0.4652 -8.78%
Mar 25, 2024 Robbert Kuipers   0.6790 Apr 19, 2024 @ 0.4914 -27.63%
Mar 25, 2024 Robbert Kuipers   0.6736 Mar 25, 2024 @ 0.6736 0.00%
Jan 17, 2024 Samuel Vuistiner   0.6000 Feb 09, 2024 @ 0.5690 -5.17%
Jan 12, 2024 רונן בן   0.7000 Feb 02, 2024 @ 0.5470 -21.86%
Dec 15, 2023 Federica Guerra   0.6500 Jan 05, 2024 @ 0.6410 -1.38%
Nov 07, 2023 Jonatan Lopez   0.9021 Dec 01, 2023 @ 0.7000 -22.40%
Aug 17, 2023 Robbert Kuipers   0.9000 Nov 30, 2023 @ 0.6820 -24.22%
Aug 17, 2023 Robbert Kuipers   0.8494 Aug 17, 2023 @ 0.9000 +5.96%
Aug 17, 2023 Robbert Kuipers   0.8494 Aug 17, 2023 @ 0.8494 0.00%
Jul 26, 2023 Samuel Vuistiner   0.8547 Aug 30, 2023 @ 0.8900 +4.13%
Jul 18, 2023 Samuel Vuistiner   1.1810 Jul 19, 2023 @ 1.1300 -4.32%
Jul 18, 2023 Peter Meško   1.1950 Nov 30, 2023 @ 0.6820 -42.93%
Jun 28, 2023 Samuel Vuistiner   1.3100 Jul 11, 2023 @ 1.3199 +0.76%
Jun 08, 2023 Samuel Vuistiner   1.8694 Jun 27, 2023 @ 1.4243 -23.81%
Jun 06, 2023 Samuel Vuistiner   1.7200 Jun 08, 2023 @ 1.7500 +1.74%
May 15, 2023 Samuel Vuistiner   1.3700 May 22, 2023 @ 1.4700 +7.30%
May 11, 2023 Samuel Vuistiner   1.4100 May 15, 2023 @ 1.3700 -2.84%
May 11, 2023 javier alonso perez   1.4100 Nov 30, 2023 @ 0.6820 +51.63%
May 10, 2023 Jordi Herrerias   1.6400 Nov 30, 2023 @ 0.6820 +58.41%
May 10, 2023 Samuel Vuistiner   1.6400 May 11, 2023 @ 1.4800 -9.76%
May 10, 2023 Oscar Canclini   1.6650 Nov 30, 2023 @ 0.6820 -59.04%
May 09, 2023 Samuel Vuistiner   1.8100 May 10, 2023 @ 1.8100 0.00%
Apr 28, 2023 Samuel Vuistiner   1.7350 May 09, 2023 @ 1.8100 +4.32%
Apr 20, 2023 Samuel Vuistiner   1.6000 Apr 22, 2023 @ 1.7100 +6.87%
Apr 05, 2023 Samuel Vuistiner   1.4400 Apr 06, 2023 @ 1.4900 +3.47%
Apr 04, 2023 Samuel Vuistiner   1.5300 Apr 05, 2023 @ 1.4400 -5.88%
Mar 27, 2023 Samuel Vuistiner   2.0200 Apr 04, 2023 @ 1.5300 -24.26%
Mar 21, 2023 JUANFRA De la sierra   1.9200 Apr 14, 2023 @ 1.7200 -10.42%
Mar 03, 2023 Samuel Vuistiner   2.1101 Mar 24, 2023 @ 2.1100 0.00%
Feb 23, 2023 Samuel Vuistiner   2.2050 Feb 24, 2023 @ 2.2500 +2.04%
Feb 06, 2023 Samuel Vuistiner   2.2638 Feb 14, 2023 @ 2.2800 +0.72%
Feb 03, 2023 Noel Jacques   2.4300 Feb 24, 2023 @ 2.1700 -10.70%
Feb 01, 2023 Samuel Vuistiner   2.4848 Feb 03, 2023 @ 2.5300 +1.82%
Jan 31, 2023 Samuel Vuistiner   2.6100 Feb 01, 2023 @ 2.5800 -1.15%
Jan 30, 2023 Samuel Vuistiner   2.3700 Jan 31, 2023 @ 2.6400 +11.39%
Jan 27, 2023 Samuel Vuistiner   2.3803 Jan 30, 2023 @ 2.4200 +1.67%
Jan 26, 2023 Samuel Vuistiner   2.6650 Jan 27, 2023 @ 2.5600 -3.94%
Jan 25, 2023 Samuel Vuistiner   2.5800 Jan 26, 2023 @ 2.4700 -4.26%
Jan 25, 2023 Samuel Vuistiner   2.4900 Jan 25, 2023 @ 2.5800 +3.61%
Jan 23, 2023 Samuel Vuistiner   2.6700 Jan 25, 2023 @ 2.4900 -6.74%
Jan 20, 2023 אבישי להב   2.6750 Feb 10, 2023 @ 2.0300 -24.11%
Jan 19, 2023 Giuseppe De Marco   3.5399 Feb 10, 2023 @ 2.0300 -42.65%
Jan 17, 2023 JUANFRA De la sierra   2.4000 Feb 10, 2023 @ 2.0300 -15.42%
Jan 09, 2023 Samuel Vuistiner   2.1017 Jan 23, 2023 @ 2.6450 +25.85%
Dec 30, 2022 Andreas Schatz   1.5200 Jan 20, 2023 @ 2.9800 +96.05%
Dec 30, 2022 David DG   1.6300 Jan 20, 2023 @ 2.9800 +82.82%
Nov 22, 2022 Peter Meško   2.1000 Dec 16, 2022 @ 1.5000 -28.57%
Nov 22, 2022 Pepe Paredes   2.1000 Dec 16, 2022 @ 1.5000 -28.57%
More
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

SLRX Comments

Write your thoughts about Salarius Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
yoni safronov
yoni safronov Jan 06, 2022 9:07AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
from half a dollar to 5 in the coming year. Just before publishing groundbreaking data
Reply
0 0
Report
KOSTAS MASOURAS
KOSTAS MASOURAS Apr 06, 2021 5:55PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
the stock falls but before December 21 will hopefully think that it raises to $15
Reply
1 0
Report
Wagner Gauer
Wagner Gauer Mar 11, 2021 12:04PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
someday some good news is going come out, and this stock it's going to shoot up hundreds of percents
Reply
0 1
Report
Dam Bog
Dam Bog Mar 11, 2021 12:04PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
yes
Reply
0 0
Report
Ken Kong
Ken Kong Mar 01, 2021 11:24AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
is this a scam stock
Reply
0 2
Report
Wagner Gauer
Wagner Gauer Mar 01, 2021 11:24AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
there are many big guys on it, i can't say for sure but i seems improbable to me
Reply
0 0
Report
derek ketcher
derek ketcher Feb 24, 2021 10:16AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
hmmm..if it drops to sub $2 before close maybe tomorrow could bring $3 with some post and premarket push
Reply
1 1
Report
Mr Mendoza
Mr_Q Feb 24, 2021 10:16AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
My interpretation of the digital meeting held today with investors is that this is a very potential trigger for increase.
Reply
0 0
Report
Mr Mendoza
Mr_Q Feb 24, 2021 9:49AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
http://investors.salariuspharma.com/news-releases/news-release-details/salarius-pharmaceuticals-present-diamond-equity-research Sounds to me like this Stock problary will increase futher after today? After this meeting with investors
Reply
0 0
Report
Auston Matcek
Auston Matcek Feb 18, 2021 11:07PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Moving to phase 2 of testing today with seclidemstat & will look to announce recent findings soon. Good signs.
Reply
0 0
Report
Anthony Cusimano
Anthony Cusimano Feb 11, 2021 1:14PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
The stock is tanking today how come ?
Reply
0 0
Report
Wagner Gauer
Wagner Gauer Feb 11, 2021 1:14PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
toidi people selling
Reply
0 0
Report
Clifton Howes
Clifton Howes Feb 11, 2021 10:04AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Buying more :)
Reply
0 0
Report
Clifton Howes
Clifton Howes Feb 11, 2021 7:09AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Expecting an increase past $4
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email